Cart
sales@molnova.com
GW 5074
CAS No. 220904-83-6
GW 5074( GW-5074 | GW5074 )
Catalog No. M13521 CAS No. 220904-83-6
A potent, selective c-Raf inhibitor with IC50 of 9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 32 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 81 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 154 | In Stock |
|
| 100MG | 186 | In Stock |
|
| 200MG | 267 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGW 5074
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective c-Raf inhibitor with IC50 of 9 nM.
-
DescriptionA potent, selective c-Raf inhibitor with IC50 of 9 nM; shows >1000-fold selectivity for raf kinase versus CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2, and c-Fms.
-
In Vitro——
-
In Vivo——
-
SynonymsGW-5074 | GW5074
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorC-Raf
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number220904-83-6
-
Formula Weight520.942
-
Molecular FormulaC15H8Br2INO2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C1NC2=C(C=C(I)C=C2)/C1=C/C3=CC(Br)=C(O)C(Br)=C3
-
Chemical Name2H-Indol-2-one, 3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-1,3-dihydro-5-iodo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lackey K, et al. Bioorg Med Chem Lett. 2000 Feb 7;10(3):223-6.
2. Yue X, et al. Eur J Pharmacol. 2006 Jul 1;540(1-3):57-9.
3. Jensen HA, et al. Cell Signal. 2015 Aug;27(8):1666-75.
molnova catalog
related products
-
GDC-0879
A potent and selective B-Raf kinase inhibitor with IC50 of 0.13 nM against purified B-Raf V600E and a cellular pERK IC50 of 63 nM in the MALME-3M cell line.
-
Xl-281
Xl-281 (BMS-908662) is a BRAF inhibitor with anti-tumor activity for the study of colorectal cancer and melanoma.
-
Kobe2602
kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD.
